Do Vibration Plates Work? A Doctor’s Evidence-Based Verdict
As humans, we’ve evolved in response to our physical environment. I’ve written about circadian rhythms and how sleep affects athletic performance. Our biology has adapted to the 24-hour solar day, but it has adapted to a second, less appreciated force, too: gravity.
The consequences of removing gravity show up fast. During long-term stays on the International Space Station, astronauts lose bone mass in space at 1% to 2% per month in weight-bearing areas. On Earth, that rate is about 0.5% per year.
The result is a dangerous, accelerated osteoporosis. Astronauts often don’t fully recover their bone density after returning home.
Lack of gravitational stimulus is one of the most potent factors behind that bone loss. Can we apply what we know about physiology and physics to improve our health? That’s the premise behind vibration plate benefits, and the answer isn’t as simple as TikTok makes it look.
Why Gravity Matters for Your Bones and Muscles
Bone cells contain mechanoreceptors that directly perceive gravitational force. When those receptors stop detecting gravity, the cells respond by thinning the skeleton. Bone resorption outpaces bone formation, and density drops.
Muscles follow a related pattern. Our muscles attach to bones through tendons and ligaments, and the contractions we use to move our body mass against gravity maintain both muscle strength and bone integrity. The muscle contractions that move your body against gravity provide traction signals to bone, which is why resistance training for longevity works.
Remove gravity, and both systems deteriorate. Increase the gravitational load, and both grow stronger. This relationship between gravity and tissue health is the physiologic principle that vibration plates aim to exploit.
What Is a Vibration Plate?
A vibration plate is a platform you stand on that oscillates at 20–40 hertz, or 20–40 times per second. You stand or squat on the plate, and the rapid oscillation forces your body to react to each subtle shift in position.
A standard barbell curl exercise illustrates how vibration plate benefits work at the muscular level. As you curl the weight upward, your bicep fibers shorten under load. That’s a concentric contraction.
When you lower the weight in a controlled motion rather than dropping it, your muscle fibers lengthen under resistance. That’s an eccentric contraction.
Both types of contraction are vital stimuli for maintaining muscle. A vibration plate compresses this cycle: each oscillation forces weight-bearing muscle groups throughout the body to concentrically and eccentrically contract in rapid succession.
The physiologic benefits are increased blood flow to muscles and skin, greater muscle activation, and a bone-strengthening traction stimulus. For anyone interested in athletic performance after 50, the question isn’t whether the stimulus exists. The question is how much it matters.
How Much Do Vibration Plate Benefits Matter?
So, do vibration plates work? The short answer: yes, but the magnitude of benefit is modest.
Bone health is like a savings account, and the goal is to keep the account solvent for a lifetime. The impact of walking 10,000 steps a day is the equivalent of tossing loose change into a piggy bank. A vibration plate steps that up to small, regular automatic deposits.
Strength training, moving more than your body’s own mass against gravity, is a steady paycheck going straight into savings. High-impact exercise (jumping, hopping, plyometrics) is a major investment with compounding interest.
On that spectrum, vibration plate benefits land toward the bottom: real, documented, but meager. The physiologic basis is sound, and studies confirm improvement in both muscle activation and bone density. For anyone who can walk and lift weights, conventional exercise delivers a far stronger stimulus.
Who Gets Real Vibration Plate Benefits?
The protocols behind FDA-approved vibration plates call for about 10 minutes of use, twice a day. The demonstrated benefits cover two outcomes: muscle activation and bone density.
For anyone with the physical ability to walk or perform resistance training, those activities provide a much stronger stimulus. Resistance training for women and men alike outperforms vibration therapy for preserving bone and muscle.
The genuine use case for vibration plate benefits is narrow: people who are frail, deconditioned, or mobility-limited and can’t tolerate the demands of conventional exercise. People with sarcopenia (age-related muscle loss) or severe deconditioning may find a vibration plate to be a viable starting point.
One critical warning: The consumer-grade vibration plates all over TikTok and Instagram don’t follow FDA-approved protocols. These products have no proven benefit and can deliver stimuli strong enough to cause harm.
Vibration Plate Benefits, Side Effects, and Social Media Myths
Whole-body vibration that’s too strong or applied too long can cause inner ear disturbances, skeletal stress, and digestive problems.
Vibration plates are contraindicated for people with kidney stones (the oscillation can dislodge them), pregnant women, and those with a history of blood clots, recent fractures, recent eye surgery, or uncontrolled vertigo. Talk to your physician before trying a vibration plate.
Social media has pinned a long list of unproven claims to vibration plates: fat burning, weight loss, detox, lymphatic drainage, cellulite reduction. No physiologic argument or clinical evidence supports any of these claims about vibration plate benefits. The same scrutiny that applies to making safe choices with supplements applies to vibration plates.
Osteoboost: An FDA-Approved Pelvic Vibration Device
One FDA-approved product takes a different approach to vibration therapy. Osteoboost isn’t a standing plate. The device wraps around the pelvic area like a girdle and delivers vibration directly to the hip bones.
Osteoboost targets postmenopausal women with osteopenia (early-stage bone thinning) who prefer to avoid medication. Daily use has shown modest improvement in bone density, but Osteoboost doesn’t rebuild bone; the device slows and prevents further loss. Women with more advanced osteoporosis or preexisting fractures need a stronger intervention.
For postmenopausal women weighing their options, bone density conversations often overlap with decisions about hormone replacement for perimenopause and other evidence-backed treatments.
Today’s Takeaways
Have you ever eaten alligator, snake, or frog legs? Every exotic meat gets the same review: “Tastes like chicken.” Why not skip the gator and just eat the chicken?
Vibration plates are the gator of the exercise world. The vibration plate benefits are real and well-documented. But for the vast majority of us, the chicken is right there: walking and resistance training.
The use case for vibration plates is narrow. People who are frail or mobility-limited and can’t perform conventional exercise may find genuine value in an FDA-approved device. Everyone else can skip the exotic option and stick with what works.
At Banner Peak Health, we bring healthy skepticism to every new health trend. We look at the evidence and match patients with the tools that fit their needs. If you’re curious about vibration plates or any other trending claim, reach out to our team.
WHOOP vs. Oura: A Doctor Who Wears One Explains How to Choose
I’m celebrating my 64th birthday this month, and birthdays tend to prompt a question: What have I learned?
As a younger man, I focused outward. I studied the world around me and assumed that the answers to happiness and success lay outside me.
With age, I’ve come to a different conclusion. The answers live within: what I bring to a job, what I need in a relationship, how I define a life well lived.
This inward turn applies to a question patients ask me regularly: WHOOP or Oura?
The answer has less to do with the specifics of either device and more to do with your willingness to examine your own physiology, formulate the right questions, and act on your findings.
Are You Tadej Pogacar?
If you watched any of the 2026 Tour de France, you saw WHOOP data on screen. WHOOP tracked Tadej Pogacar, Mathieu van der Poel, and Jasper Philipsen throughout their preparation and racing, then compared their numbers against more than 15,000 active members.
Resting heart rates for the three riders ranged between 38 and 44 beats per minute, 10 to 17 beats lower than age-matched cyclists. Van der Poel’s heart rate variability averaged 143 milliseconds, exactly double the 71-millisecond average of his comparison group.
These numbers reflect a level of cardiovascular fitness that separates world-class athletes from the rest of us. Pogacar logged 578 hours on the bike and more than 200 cycling sessions in the build-up alone. For an athlete competing in a three-week race where seconds separate the winner from the field, every incremental bit of wearable data can make a meaningful difference.
You aren’t Tadej Pogacar. Neither am I. So what does the WHOOP vs. Oura conversation look like for the rest of us?
The Real WHOOP vs. Oura Question
Before comparing specs, ask yourself a better question: Does knowing more about your own physiology make you curious, or anxious?
Some people thrive on the process. They look for patterns in their heart rate variability and recovery data. They’re willing to experiment with bedtime routines, alcohol intake, meal timing, and training intensity to see what moves the needle.
For someone with this personality, a consumer wearable can be profoundly life-changing. These devices answer the questions instinct can’t: how much sleep you’re getting, how alcohol affects your recovery, whether you’re overtraining, and whether your bedtime routine makes a measurable difference.
Wearables like WHOOP and Oura provide the raw material for what we call the metric-derived empowerment cycle: you measure, you learn, you change behavior, and you measure again. I first described this cycle in the context of continuous glucose monitoring. For the right person, the feedback loop can reshape how you manage your health.
For others, the data proves more burden than benefit. The devices collect dust in a drawer, or worse, create a new source of stress.
When WHOOP and Oura Data Backfires
Wearable data becomes counterproductive when it controls your decisions instead of informing them. Whether you’re wearing a WHOOP or an Oura Ring, the risk is the same.
Sleep is the clearest example. You can’t choose to fall asleep; you can only set up the right conditions and let your body do the rest. Worrying about an arbitrary WHOOP or Oura sleep score can, paradoxically, compromise the sleep that drives athletic performance.
Doctors have a name for this: orthosomnia, where people become so anxious about their wearable’s sleep scores that their sleep quality declines. The same dynamic can apply to heart rate variability readings and daily readiness scores, where obsessing over numbers defeats the purpose of tracking them.
I personally thrive on these numbers. My wife, on the other hand, dismisses the whole process by saying, “I don’t want to know.” The device matters less than the person wearing it.
The WHOOP vs. Oura Learning Curve
With any wearable, expect a law of diminishing returns.
In my first several months wearing an Oura Ring, I learned an enormous amount. I tracked how alcohol affected my sleep and recovery. I connected consistent sleep timing to higher readiness scores and linked meal timing to changes in my heart rate variability.
The data reshaped my daily habits in ways I hadn’t anticipated. After I incorporated those changes, the WHOOP vs. Oura question went from “What can I learn?” to “What’s left to learn?” The urgency faded, and the daily check-ins stopped delivering new insights.
I’m wearing my Oura Ring three years later, though. The company’s ability to innovate keeps the device on my finger.
Recent updates now capture data on nocturnal blood pressure dips and pulse wave velocity. The same sensor platform continues to produce new physiologic data I hadn’t expected when I first put the ring on.
WHOOP vs. Oura: What Actually Sets Them Apart
I’m not going to rank each device’s sensors against each other. The two share a tremendous overlap in physiologic parameters: heart rate, heart rate variability, sleep staging, skin temperature, and blood oxygen saturation. Comparing their algorithms for accuracy belongs in a lab, and it misses the more important point.
The most distinguishing feature in the WHOOP vs. Oura comparison comes down to the emotional context, almost the personality, with which each device communicates your data.
Oura tends to be gentler and more empathetic. If you wake up with a low sleep score, the app will tell you to take it easy and that tomorrow will be a better day. Oura is the caring friend who helps you find your balance.
WHOOP takes a more direct approach. The app reads like a driven coach who pushes you to train harder. WHOOP’s messaging leans athletic and performance-oriented.
Both devices run on subscriptions, though the models differ. WHOOP bundles hardware into a yearly membership ($199 to $359 per year, depending on tier). Oura requires a one-time ring purchase (starting at $349 for the Ring 4) plus a $5.99 monthly subscription.
Over three years, Oura tends to cost less once you’ve paid off the initial hardware.
The choice comes down to a single question: Do you want a caring friend or a performance-oriented coach? Different personalities respond to different messaging. The friend-vs.-coach dynamic is probably the most meaningful distinction separating WHOOP from Oura.
Today’s Takeaways
If you’re choosing between WHOOP and Oura, or deciding whether to wear a consumer wearable at all, the most important questions are internal.
Does more information about your own physiology help you modify your lifestyle? Or does more data create anxiety that diminishes your daily enjoyment and overall productivity?
Do you want to be pushed harder in your athletic performance? Or are you looking for help finding your balance?
At Banner Peak Health, we’re eager to explore new technology and incorporate what we find valuable for our patients. We do this to get to know you and provide personalized, concierge-level care.
We’d rather help you identify and fit the right tools for your health than push any trend or product. Reach out to our team to discuss which approach fits you.
Fall Vaccine Update 2026
Fall is coming. The days are getting shorter, kids are back in school, and once again it’s time for Banner Peak Health’s annual vaccine update.
We’re covering our recommendations for influenza, respiratory syncytial virus (RSV), and COVID vaccines, along with an extra credit section on the potential benefits of azelastine nasal spray in reducing infection risk.
Influenza Vaccine
Let’s start with the easy one: Get an influenza vaccine every year.
Influenza continues to cause substantial illness, hospitalization, and death, particularly among older adults. We have decades of experience with influenza vaccines and good evidence that vaccination reduces the likelihood of serious illness.
This year’s influenza vaccine is trivalent, meaning it protects against three influenza viruses expected to circulate: two influenza A viruses (H1N1 and H3N2) and one influenza B virus. The specific strains have been updated for the 2026–2027 season to better match the influenza viruses expected to circulate this winter.
Why We Prefer Flublok
This year, Flublok® is our preferred influenza vaccine for our adult patients, including those over 65.
Flublok has two important advantages.
First, it contains three times as much influenza hemagglutinin (HA) antigen as a standard-dose influenza vaccine. Hemagglutinin is the part of the influenza virus the immune system learns to recognize. More antigen provides a stronger stimulus to the immune system, which is particularly useful as our immune response weakens with age.
Second, Flublok is manufactured differently.
Traditional influenza vaccines are produced by growing influenza virus in chicken eggs. Unfortunately, influenza viruses don’t particularly care that vaccine manufacturers would like them to remain unchanged.
As they adapt to growing in eggs, small mutations can occur. These “egg-adaptive” changes can make the resulting vaccine slightly different from the influenza virus circulating in people.
Flublok avoids this problem. It uses recombinant technology to manufacture the influenza protein directly rather than growing the virus in eggs. The result is a vaccine antigen that more precisely matches the strain selected for that year’s vaccine.
For people 65 and older, several enhanced influenza vaccines are available. All are reasonable choices. At Banner Peak Health, we prefer Flublok.
When to Get Vaccinated
We recommend receiving your influenza vaccine in October, rather than rushing out to get it as soon as pharmacies start advertising flu shots.
Protection is strongest during the months immediately following vaccination. Influenza season in California can extend well into the spring, so waiting until October shifts that window of maximum protection later.
One exception: travel beats perfect timing. If you’re taking a major trip in September or October, get vaccinated at least a couple of weeks before you leave.
Key Influenza Vaccine Points:
- Get an influenza vaccine every year.
- We prefer Flublok for our adult patients, including those over 65.
- October is the best time to receive it.
- If you’re traveling earlier, get vaccinated before your trip.
RSV Vaccine
RSV, or respiratory syncytial virus, usually causes what feels like a bad cold. But as we get older, it becomes a more consequential disease.
RSV can cause pneumonia, worsen heart or lung disease, and lead to hospitalization. The greatest risks occur in older adults, particularly people over 75 and those with significant chronic medical conditions.
When RSV vaccines first became available in 2023, we were cautious. Initial clinical trials confirmed the vaccines prevented RSV illness, but little evidence showed they prevented the outcomes we cared about most: hospitalization and death. Early data raised concerns about rare neurologic complications, too.
Three years of additional experience have made us considerably more comfortable with these vaccines.
Our preferred RSV vaccine is Pfizer’s Abrysvo®.
For people who haven’t been vaccinated, we recommend RSV vaccination for everyone 75 and older and for adults 50–74 who have medical conditions that put them at increased risk for severe RSV. These include significant heart or lung disease, diabetes with complications, chronic kidney disease, immune suppression, frailty, and residence in a nursing or assisted-living facility.
Unlike the flu vaccine, RSV vaccination isn’t an annual event. If you’ve already received an RSV vaccine, you don’t need another one this year.
Key RSV Vaccine Points:
- If you’re 75 or older, get an RSV vaccine if you haven’t already.
- If you’re 50–74 and at increased risk, we recommend vaccination.
- RSV vaccination isn’t currently an annual vaccine.
- If you received an RSV vaccine previously, you don’t need another one this year.
- If you aren’t sure whether you qualify as high risk, ask us.
COVID Vaccine
Like the influenza vaccine, the COVID vaccine is updated to better match circulating strains. For 2026–2027, the vaccine has been updated to target XFG, a descendant of the Omicron JN.1 family.
Think of this in much the same way as the annual influenza vaccine. We aren’t starting over every year. We’re updating the photograph we show your immune system so it more closely resembles the virus it’s likely to encounter.
Banner Peak Health is using Pfizer’s updated mRNA COVID vaccine this year.
COVID vaccination is much better at preventing serious disease than at preventing every COVID infection. You can be appropriately vaccinated and still get COVID. The more meaningful question is whether vaccination decreases your chance of becoming seriously ill.
For older and higher-risk adults, the answer is yes.
Once a Year or Twice a Year After 65?
This is where things become less black and white.
Protection from COVID vaccination declines with time, and older adults tend to lose that protection more quickly. That creates a reasonable argument for giving some people over 65 a second COVID vaccination about six months after their fall vaccination.
But should everyone over 65 automatically get two COVID vaccines every year?
We don’t think the evidence supports such a simple rule.
An active, healthy 66-year-old with previous COVID infections and no major medical problems is very different from an 82-year-old with heart disease, diabetes, and chronic lung disease.
Our approach is to individualize the decision. We favor a second dose about six months later for the oldest and highest-risk patients. For healthy adults in their late 60s and early 70s, one updated vaccine each year may be reasonable.
If you recently had COVID, you don’t need to rush to get vaccinated. Your infection has just stimulated your immune system. In most circumstances, waiting about three months before vaccination is reasonable.
Key COVID Vaccine Points:
- COVID vaccination is most valuable for preventing severe disease, hospitalization, and death.
- Older adults and people with significant medical conditions derive the greatest benefit.
- This year’s vaccine has been updated to target XFG.
- Banner Peak Health is using Pfizer’s mRNA COVID vaccine this year.
- If you recently had COVID, you can wait about three months before vaccination.
- For adults over 65, whether to receive another dose about six months later is an individualized decision. The older and higher risk you are, the stronger the argument for another dose.
Can I Get My Flu and COVID Vaccines Together?
Yes.
You can receive influenza and COVID vaccines at the same visit. Most people don’t need to separate them.
Separating them is fine if you tend to feel poorly after vaccination and would rather deal with one at a time.
We’re somewhat more inclined to give the RSV vaccine separately. It’s still relatively new and needs to be observed more closely for side effects.
Extra Credit: A Nasal Spray to Reduce Your Risk?
Vaccines improve your immune system’s ability to fight COVID after you’re exposed. But what if you could make it harder for the virus to get in the door in the first place?
We covered how nasal sprays may prevent COVID in a previous post, and a new clinical trial strengthens the case.
Azelastine is an inexpensive, over-the-counter antihistamine nasal spray used for decades to treat allergies. COVID and many other respiratory viruses initially establish themselves in the nose, making the nasal passages a logical place to try to prevent infection.
In 2025, researchers published the CONTAIN trial, involving 450 healthy adults who used either azelastine nasal spray or a placebo three times daily for 56 days.
The results were impressive: 2.2% of people using azelastine developed COVID compared with 6.7% using placebo, a roughly 69% reduction in risk. The azelastine group had fewer rhinovirus infections, too, one of the viruses behind the common cold.
This was one relatively small study, so we need more trials to confirm the benefit. But azelastine is inexpensive, available without a prescription, and has been used safely for decades. The most common downsides are minor nasal irritation and that notoriously unpleasant azelastine bitter taste.
We think it’s reasonable to consider azelastine during higher-exposure situations: air travel, conferences, crowded gatherings, or periods when respiratory viruses are circulating heavily. The dose is one puff per nostril twice a day.
Think of it as a belt-and-suspenders strategy: vaccination prepares your immune system to fight the virus; azelastine may make it harder for the virus to establish an infection in the first place.
The Bottom Line
Influenza: Get vaccinated every year. We prefer Flublok for our adult patients, including those over 65. October is the best time.
RSV: If you’re 75 or older and haven’t previously received an RSV vaccine, get one. If you’re 50–74 and have significant risk factors, we recommend vaccination. RSV vaccination isn’t currently an annual vaccine.
COVID: We recommend an annual updated COVID vaccine, particularly for older adults and anyone at increased risk for severe disease. Banner Peak Health is using Pfizer’s mRNA COVID vaccine this year. For people over 65, whether to receive another dose about six months later deserves an individualized discussion.
Extra credit: Consider azelastine nasal spray during travel, conferences, crowded gatherings, or other periods of increased exposure. The evidence is preliminary, but a randomized clinical trial suggests it may provide another layer of protection.
Contact our team if you’re uncertain about your individual recommendations.
Best of Health,
Barry Rotman, MD
Waheeda Hiller, MD
Lindsay Klein, MD
Ari Katz, MD
How We Distinguish Real Longevity Medicine From Snake Oil
With my two daughters away at school, it was time to sell the old family Subaru. The car had served us through 12 years of road trips, errands, and driving lessons. I went to CarMax and filled out a detailed questionnaire about the vehicle: mileage, accident history, engine warning lights, and equipment condition.
CarMax runs its entire business on one idea. The company builds a quantitative longevity index for every car it considers buying. Getting that index right is the foundation of the business model.
The connection to medicine struck me before I finished the form. We’re living through a surge of interest in what people call “longevity medicine,” a phrase that means different things to different people. The concept touches on a universal human desire: to push back the forces of aging and live a long, productive life.
Much of the longevity industry is selling promises it can’t back up with data. At Banner Peak Health, where we bring disciplined evaluation to annual health assessments and preventive care, patients walk in with questions about biological age tests, rapamycin prescriptions, and NAD+ infusions. My answer catches them off guard.
Two Categories of Longevity Technology
When I think about longevity medicine, I divide the technology into two categories: diagnostic and therapeutic.
Diagnostic technology centers on the concept of biological age. A growing number of tools claim to measure how well a particular individual is aging: DNA methylation clocks, telomere length assays, and other physiologic biomarkers. Each one promises to tell you whether you’re aging faster or slower than your birth certificate suggests.
Therapeutic technology occupies the other side. This category includes the supplements, pharmaceuticals, and dietary protocols that people are either taking or selling to extend lifespan: rapamycin, NAD+ precursors, and extreme calorie restriction. I’ve covered making safe choices with supplements in a previous post, and that guidance applies to longevity products.
Both categories face the same fundamental problem: neither has produced the scientific proof needed to show it can help you live longer.
Why Biological Age Testing Falls Short
A diagnostic test has value only when it leads to a therapy that produces a better outcome for the patient. You can measure a person’s biological markers till the cows come home, but if those measurements don’t drive a treatment that helps the patient live longer, the diagnosis has no value.
This is the core issue with biological age clocks. They can track how you’re aging, but none has led to a therapy that helps you live longer.
I discussed a similar gap in a post on at-home hormone testing. The longevity diagnostic space is a bridge to nowhere: full of measurements, but without the data to connect them to longer, healthier lives.
Why Longevity Therapeutics Lack Proof
The therapeutic side of longevity medicine faces its own challenge. Generating valid science around lifespan is a major undertaking. Human beings aren’t laboratory mice with 18-month life expectancies, and running a study to determine whether a drug or supplement helps humans live longer takes decades.
What the science of longevity needs, and doesn’t yet have, is a validated intermediate endpoint for aging.
An intermediate endpoint is a measurable marker with a proven causal relationship to the outcome you’re studying. A good example comes from cardiovascular medicine: ApoB. We’ve covered how to lower ApoB in a previous post, and the science is clear: reduce ApoB, and you’ll reduce atherosclerotic vascular disease and live longer.
Longevity medicine doesn’t have an equivalent of ApoB. Without a validated intermediate endpoint for aging, we lack the methodology to evaluate the flood of supplements and drugs claiming to extend life.
The 10 Interventions Proven to Prolong Life
Setting aside the hype, the interventions with the strongest scientific backing for living longer are familiar.
The 10 most potent interventions, ranked by strength of evidence:
- Regular physical activity, including aerobic exercise and resistance training
- A healthy dietary pattern (Mediterranean, DASH, or plant-based)
- Maintaining a healthy weight
- Not smoking, or quitting
- Strong social connections and avoiding isolation
- Good quality sleep
- Cognitive engagement and mentally stimulating activity
- Limiting alcohol consumption
- Stress management and psychological well-being
- Controlling cardiometabolic risk factors (hypertension, diabetes, and elevated cholesterol)
We’ve covered several of these topics in previous posts. Exercise is the real fountain of youth, and the traditional medical approach to sleep is overdue for a rethink. We’ve discussed the latest on alcohol guidelines and why monitoring your hemoglobin A1C levels matters for metabolic health.
Notice what’s absent from this list: any high-tech biological testing or pharmacologic agent designed to extend your life. Not a single purpose-built “longevity” product appears. The interventions with the strongest backing are the same ones doctors have been recommending for decades: move your body, eat well, sleep well, stay connected to other people, and manage the conditions that shorten life.
How Banner Peak Health Approaches Longevity
The list above points to an uncomfortable truth. The longevity industry attracts enormous investment, and clinics across the country charge tens of thousands of dollars for proprietary biological age tests and supplement protocols. I have friends who run these clinics, and I respect their intentions.
But consider a thought experiment. You’ve spent tens of thousands of dollars at a proprietary longevity clinic. Now call that clinic at 4 p.m. on a Friday and tell them you have had worsening chest pain every time you climb the stairs and that you are worried.
In all likelihood, the clinic will completely disown the problem and direct you elsewhere despite a very real imminent threat to your “longevity.”
At Banner Peak Health, we do things differently. We’re committed to longevity, but science guides our approach, not profit.
We use continuous glucose monitors to give patients real-time feedback on how dietary choices affect metabolic health. We’ve built a parasympathetic rehabilitation program around the TruVaga vagus nerve device to help patients lower their stress load. We employ the Galleri test for early cancer detection to catch cancers before symptoms appear.
We use VO2 max as a diagnostic tool to guide athletic optimization. We work with Sleep Image technology to help patients improve their rest, and we partner with nutritionists and physical therapists to improve their diet and maintain physical fitness.
Every one of these technologies ties back to the evidence-based list. Each one strengthens a proven pillar of longevity. In upcoming posts, we’ll examine specific technologies and trends through this same lens: evaluating what works, what doesn’t, and what the science supports.
Today’s Takeaways
The longevity industry is booming, generating excitement and attracting enormous investment. But when I look at the data, the picture is clear: the most powerful tools for living longer are the same ones we’ve recommended for decades.
Move your body, eat well, and get quality sleep. Stay connected to the people around you, and control the medical conditions that shorten your lifespan.
At Banner Peak Health, we’ve built our practice around these fundamentals, in step with the evolution of concierge medicine toward evidence and prevention. We adopt new technology when the data supports it, not when the marketing hype peaks. We stay in relationship with our patients for the long haul: through annual physicals, acute crises, and the quiet daily work of living well.
The term “longevity medicine” is a fad. Our practice is not.
If you’d like to discuss how our approach can support your health goals, schedule a conversation with our team.
Did the Galleri Cancer Test Fail? A Doctor’s Interpretation of the Latest Data
“In the land of the blind, the one-eyed man is king.”
This adage comes to mind whenever I think about cancer screening. A few years ago, I introduced Banner Peak Health patients to the GRAIL Galleri test, a screening technology so advanced it would’ve been unimaginable when I was in medical school in the 1980s. This spring, the NHS-Galleri study released its three-year results, and the headlines weren’t kind.
Some proclaimed the test had failed. Declaring failure misses the point.
What follows is my reading of the evidence, why I’m not discouraged, and why Banner Peak Health continues to recommend screening to appropriate patients.
A Blind Spot in Cancer Screening
We have established, evidence-based screening guidelines for only five cancers: breast, prostate, lung, colon, and cervical. Five. That’s it.
The five cancers with screening guidelines aren’t even the most lethal. Pancreatic cancer, ovarian cancer, liver cancer, stomach cancer, and dozens of others have no routine screening at all. Physicians and patients are blind to these diseases until symptoms appear, and by then the cancer is often advanced.
The Galleri test is the one-eyed man. It’s imperfect, but it offers a way to screen for cancers we’ve never had a tool to detect.
How the Galleri Test Detects Cancer
Before we talk statistics, I want to put the science in context.
We already encourage our members to stay current on their bloodwork. Galleri adds cancer screening to the routine blood draw.
Cells throughout our bodies constantly die and regenerate. As each cell dies, it releases fragments of DNA into the bloodstream, where they circulate for a few hours before the body breaks them down. At any given moment, billions of DNA fragments from millions of dying cells flow through our blood.
Cancer cells, driven by abnormal biology, grow and die faster than healthy cells. Their faster turnover floods the bloodstream with cancer-derived DNA. These cancer fragments carry a distinct chemical signature: a pattern of methylation (methyl groups attached to the DNA) that flags them as cancerous and, in most cases, pinpoints the anatomical site of origin.
A Galleri screening draws several vials of blood and sifts through billions of fragments to find the handful from cancer. Its sensitivity reaches 76.3% across all stages for the 12 deadliest cancers, the ones responsible for two-thirds of cancer deaths in the United States. Its specificity sits at 99.5%.
In practical terms, for every 200 people screened, about two will test positive. One will be a true positive; the other a false alarm.
The Galleri test gets more accurate as cancers get more aggressive. Traditional screening tools like mammograms and PSA tests tend to catch slow-growing, indolent tumors that may never kill the patient.
Nastier cancers divide faster, shed more DNA, and produce a stronger signal. The test catches the tumors most likely to end a life.
What the NHS-Galleri Study Actually Found
The NHS randomized 140,000 participants into two equal groups. Half received annual screening for three years; the other half continued standard care. The primary endpoint was a reduction in combined stage three and four cancer diagnoses.
Researchers chose cancer stage at diagnosis as a surrogate for what they wanted to know: can screening save lives? Proving a mortality benefit would have required far more participants and many additional years of follow-up.
The study didn’t meet its primary endpoint. Researchers found no statistically significant reduction in combined stage three and four cancers across the full three-year period. The press declared the test had failed.
The Galleri test’s sensitivity and specificity improved over prior data, and by year three, the screened group showed a statistically significant drop in stage four diagnoses. Stage four is the deadliest category. A reduction in stage four diagnoses signals the test may catch aggressive cancers before they advance to their worst form.
The NHS-Galleri findings didn’t produce a definitive verdict. They gave us a refined estimate of probability. For those of us committed to reducing our cancer risk by every available means, does the probability of benefit justify action?
How Certain Do You Need to Be About the Galleri Test?
We live in a culture that wants clean answers. Is the test good or bad? Does it work or not?
Medicine rarely deals in good-or-bad binaries. I make probabilistic assessments every day. When a patient presents with chest pain, I don’t wait for certainty before ordering tests.
I estimate a probability, and once it crosses a threshold, I act. The same logic applies to interpreting the NHS-Galleri data and to the executive physicals we perform at our practice. Whether to use the Galleri test comes down to probability, not certainty: has the evidence crossed your personal threshold for action?
The threshold for action depends on who’s making the decision.
My threshold is low. My mother died at age 60 from metastatic breast cancer. I watched my father go from bike-commuting to a full-time dental practice at 70 to dead from pancreatic cancer in under a year.
I ordered my first Galleri screening the moment it became available. Every year, when I get a negative result, I know the test had about an 84% chance of catching pancreatic cancer if I had it. A negative Galleri result matters.
Medicare or the NHS must weigh Galleri’s potential benefit against population-level costs. Billions in testing, follow-up imaging, and specialist referrals pull dollars from other health care priorities. Government agencies are right to demand a higher standard of proof before spending at that scale.
Individual and institutional perspectives aren’t contradictory. They reflect different thresholds, grounded in distinct responsibilities. A government program can rationally decline to fund widespread adoption at this stage of evidence.
A patient sitting in my office, with a concerning family history, can rationally choose to screen today. Both decisions can be correct.
Today’s Takeaways
The NHS-Galleri study didn’t deliver the clean failure some headlines claimed. The study produced mixed results that look better or worse depending on your perspective.
The Galleri test’s sensitivity remains strong, particularly for the deadliest cancers, and its 99.5% specificity keeps false positives rare. Aggressive, fast-growing malignancies produce a stronger signal than indolent ones. For individual patients weighing risk and benefit, the test has earned its place in a cancer screening plan.
At Banner Peak Health, our concierge medicine model gives us the time to discuss whether Galleri screening is right for each patient. For patients who can manage the out-of-pocket cost and accept a false positive rate of one in 200, the test remains a good investment in long-term health. If you’re wondering whether multi-cancer screening makes sense for you, bring the question to your next visit.
Vagus Nerve Stimulation Exercises: The Daily Reps That Train Your Nervous System
You can train your nervous system the same way you’d train a bicep: with specific reps, consistent practice, and progressive challenge. I call the drills below “parasympathetic push-ups,” daily reps that strengthen your body’s capacity to recover from stress.
Modern life overwhelms our sympathetic nervous system, the fight-or-flight wiring that primes us for short-term survival. We don’t need help revving that engine; daily stress does it for us. The missing piece is training the parasympathetic system: the network that slows the heart, calms inflammation, and manages our stress response.
The 10 vagus nerve stimulation exercises below are ranked from strongest to weakest evidence, with grades and practical guidance for each. We’ll address HRV as a stress management tool later, including what it can and can’t tell you about progress.
The Vagus Nerve: Your Body’s Weighted Keel
For years, I pictured the autonomic nervous system as a seesaw: sympathetic on one side, parasympathetic on the other, alternating back and forth. I’ve since replaced the seesaw with a sailboat carrying a weighted keel.
Above the waterline, the sail catches wind and drives the boat forward. The wind leans the boat over, and that forward momentum is the sympathetic system doing its job.
Below the waterline, a weighted keel prevents the boat from capsizing. When the wind dies, the keel rights the boat back to vertical.
The keel is the parasympathetic nervous system. Life’s stressors, illness, poor sleep, and trauma all act as wind trying to tip us over.
Successful aging depends on the keel’s ability to right the boat, a process physiologists call homeostasis. We need to strengthen the keel, not just wait for the wind to stop.
The primary highway of the parasympathetic system is the vagus nerve, one of 12 cranial nerves and the longest in the body. It originates in the brainstem, travels through the neck (right next to the carotid artery), and branches into the heart, lungs, stomach, liver, pancreas, kidneys, and intestines.
Vagal activity lowers blood pressure, reduces heart rate, controls digestion, opens the airways, and dials down the body’s inflammatory signaling.
“Vagal tone” describes how strong and responsive the vagus nerve is. The goal of every vagus nerve stimulation exercise is to make vagal tone as buff as possible.
10 Vagus Nerve Stimulation Exercises, Ranked by Evidence
If we were talking about chemotherapy or surgery, we’d demand the strongest possible evidence before proceeding. Every item on the list below is safe, inexpensive, and accessible.
The evidence bar for vagus nerve stimulation exercises can be lower when the risk is near zero and the cost is negligible. Even the entries near the bottom carry almost no downside.
The ranking runs from strongest evidence to most preliminary.
1. Slow Deep Breathing
Evidence: strong.
Breathing at six breaths per minute, five counts in and five counts out, is the simplest and best-supported exercise on this list. The slow rhythm activates the parasympathetic system directly. For a step-by-step protocol, see our guide to belly breathing techniques.
2. Regular Aerobic Exercise
Evidence: strong.
Study after study has documented the value of regular aerobic exercise across almost every health metric we can measure. Improved vagal tone now belongs on that list.
3. Cold Exposure
Evidence: moderate to strong.
Cold water immersion and cold showers create deliberate physical stress. In sailboat terms, cold exposure tips the boat over on purpose so the keel can practice righting itself. Repeated cold challenges train the parasympathetic system to mount a faster, stronger response.
4. High-Quality Sleep
Evidence: moderate to strong.
Quality sleep improves every health metric we have ever measured. Vagal tone is on the list.
If you follow our blog, you’ve heard me say the same about exercise; the overlap between sleep and athletic performance benefits is almost complete.
5. Yoga, Tai Chi, and Qigong
Evidence: moderate.
Yoga, tai chi, and qigong leverage thousands of years of cultural wisdom about the connection between movement and breathing. If human beings have practiced these disciplines for millennia, there’s good reason to think the physiological effects are real. Controlled breathing paired with slow, deliberate movement stimulates vagal activity through multiple pathways at once.
6. Omega-3 Fatty Acids
Evidence: growing.
Research links omega-3 fatty acids to improved cardiovascular and cognitive outcomes. Improved vagal tone may be one mechanism behind those benefits, though researchers are still sorting out whether omega-3s affect vagal tone directly or as a downstream result of other physiological changes.
7. Transcutaneous Vagus Nerve Stimulation
Evidence: moderate but mixed.
The vagus nerve runs through the neck just millimeters below the skin surface, right alongside the carotid artery. The nerve’s proximity to the surface makes it accessible to low-level electrical stimulation delivered through the skin.
Devices like Truvaga deliver targeted pulses in a two-minute, twice-daily protocol. For a deeper look at how Truvaga works and our lending library, see the dedicated post.
8. Mindfulness and Meditation
Evidence: moderate but mixed.
The data on meditation and vagal tone are inconclusive, but the risk-benefit ratio makes the practice an easy recommendation. Meditation costs nothing, carries no risk, and the broader benefits for stress, mood, and focus are well-documented.
9. Positive Social Connection
Evidence: growing.
Humans evolved as social creatures. A person living in isolation is not in his or her optimal evolutionary state.
Research links loneliness with worse psychological and physical health outcomes. Meaningful social connection correlates with better health markers, and improved vagal tone may be one mechanism.
10. Humming, Chanting, and Singing
Evidence: preliminary.
The vagus nerve passes through the larynx, throat, and lungs. The working hypothesis is that vocal vibration provides a mechanical stimulus to the vagal fibers running through those structures, similar to how a transcutaneous device delivers an electrical signal through the neck. Research is early, but the activity carries zero risk and has obvious social benefits.
A Realistic Look at HRV and Vagal Tone
Heart rate variability is the best available proxy for vagal tone. HRV norms vary by age, and population-level data show the metric improves with the exercises above.
At the individual level, the HRV signal is subtle and noisy. For any one person tracking HRV on a Garmin or Oura Ring, day-to-day fluctuations overwhelm any signal from a breathing practice or cold plunge. The statistical benefit of vagal training shows up across populations, not on a single wristband.
Don’t let HRV’s limitations discourage you. The vagus nerve stimulation exercises on this list work through mechanisms HRV can’t capture in real time. Commit to consistent practice and let the benefits accumulate, rather than chasing daily numbers on a screen.
Parasympathetic Rehab at Banner Peak Health
At Banner Peak Health, vagal tone is a clinical priority. We’re building a multidisciplinary parasympathetic rehab program that incorporates vagus nerve stimulation exercises, lifestyle coaching, and the Truvaga lending library.
The lending library lets patients borrow a Truvaga device for a month before committing to a purchase. The protocol is simple: two minutes per side, twice daily. Our approach to concierge medicine gives us the time to walk each patient through the program and adjust it to their needs.
Today’s Takeaways
Vagus nerve stimulation exercises are the parasympathetic push-ups your body needs to stay balanced as you age. The 10 practices above range from well-supported (slow breathing, aerobic exercise) to preliminary (humming and chanting), but every item on the list is safe, cheap, and accessible.
Start with slow deep breathing at six breaths per minute. Stack additional practices as they fit your routine. And if you’re interested in athletic performance after 50, consider how parasympathetic training fits alongside the strength and endurance work you’re already doing.
At Banner Peak Health, we help patients build a personalized parasympathetic rehab program. If vagal tone or the Truvaga lending library interests you, bring it up at your next visit.
The ApoB Test: The Cardiovascular Marker You May Never Have Heard Of
What do the United States, Liberia, and Myanmar have in common? They’re the only three countries on the planet that don’t use the metric system.
The rest of the world’s 7.85 billion people measure in meters and kilograms. We’re still using the U.S. customary system, a clunky relic in which 12 inches equal one foot and 5,280 feet equal a mile.
Our system isn’t better. The metric system is simpler, more logical, and universally adopted. But we stay the course out of inertia: it’s the way we’ve always done it, and the effort to change feels too large.
The situation in cardiovascular medicine is strikingly similar. American physicians continue to rely on LDL cholesterol (LDL-C) as the primary treatment target for coronary artery disease, even though a more accurate marker, apolipoprotein B (ApoB), has been available for years.
The Europeans have already made the switch. We’re still debating it.
Europe vs. America: A Guideline Gap
As early as 2019, the ESC and EAS dyslipidemia guidelines stated that ApoB was “a more accurate marker of cardiovascular risk than LDL-C.” They provided specific ApoB treatment targets.
By contrast, the 2018 ACC/AHA cholesterol management guidelines mentioned ApoB only as a “risk-enhancing factor to consider in borderline patients,” with no specific treatment targets or recommendations.
Fast forward to 2026: the ACC/AHA dyslipidemia guidelines have given ApoB greater prominence, but the recommendations remain almost entirely built around LDL and non-HDL-C as primary targets.
The U.S. lags behind Europe in formally adopting the ApoB test as a treatment target, and the delay costs patients early detection of cardiovascular risk. The reasons mirror the metric system problem: decades of randomized controlled trials used LDL-C as the endpoint, clinical workflows are built around LDL targets, and switching requires more effort than staying the course.
What ApoB Is and Why It Matters
Apolipoprotein B (ApoB) is a protein that sits on the surface of every lipoprotein particle in your blood containing potentially hazardous cholesterol: LDL, VLDL, IDL, and Lp(a).
Exactly one ApoB molecule sits on each particle. That means measuring ApoB counts the exact number of dangerous particles circulating in your bloodstream.
Picture two highways (your arteries). Highway A has 100 large trucks, each carrying a heavy load of cargo (cholesterol). Highway B has 200 smaller sedans, each carrying a lighter load. If you measure only the total amount of cargo on each highway, the two might look equivalent.
But Highway B, with twice as many vehicles, has a much higher probability of fender benders: collisions where the contents spill into the vessel walls. That spillage, cholesterol being absorbed into artery walls, is the disease process of atherosclerosis.
The ApoB test counts the vehicles on the highway, not just the total cargo, and the number of vehicles predicts crashes more accurately. Cholesterol isn’t inherently dangerous.
It performs normal physiologic functions throughout the body. The danger arises when lipoprotein particles crash into vessel walls and deposit their cholesterol where it doesn’t belong.
Four Reasons the ApoB Test Is the Better Marker
First, ApoB is directly measured. LDL-C is calculated from other values using an equation (the Friedewald formula), introducing a source of mathematical error. A direct measurement is more precise.
Second, ApoB doesn’t require fasting. The LDL-C calculation does. This sounds trivial, but it affects how reliably patients get tested. Fasting requirements create compliance barriers that reduce testing frequency.
Third, ApoB captures all atherogenic particles in a single number. LDL-C reflects only the cholesterol within LDL particles, an incomplete accounting. The cholesterol distributed across VLDL, IDL, and Lp(a) particles goes uncounted; ApoB catches them all.
Fourth, the ApoB test is a stronger predictor of cardiovascular events than LDL-C. It more accurately identifies who will have a heart attack. That’s the metric that matters most.
What Your ApoB Number Means
When you get your ApoB results, you’ll receive a number measured in milligrams per deciliter (mg/dL). Interpreting that number requires the same nuance we’ve discussed in the context of other lab values like hemoglobin A1C: “normal” and “optimal” aren’t the same.
Some labs report ApoB as normal at levels ranging from 120 to 130 mg/dL. That range isn’t healthy. In a society with widespread hyperlipidemia, average is not a target to aim for.
Optimal ApoB levels fall below 90 mg/dL for most adults and below 80 mg/dL for individuals at high cardiovascular risk, including those with diabetes, chronic kidney disease, strong family history, or evidence of early heart disease.
This gap between “normal” and “optimal” has particular clinical relevance for patients with certain metabolic profiles. When HDL runs normal-to-low and triglycerides run normal-to-elevated, a constellation seen in insulin resistance, prediabetes, type 2 diabetes, metabolic syndrome, and obesity, LDL-C becomes less accurate as a risk predictor. ApoB remains reliable.
The numbers are striking: 50–60% of U.S. adults have one or more of these metabolic risk factors. That means roughly half of American adults have a lipid metabolism profile in which LDL-C alone can be misleading.
Getting an ApoB Test
Some physicians don’t order the ApoB test. It isn’t new, expensive, or hard to obtain.
The barrier is the same clinical inertia that keeps us off the metric system. EHR order sets, quality metrics, prior authorization algorithms, and decades of habit all revolve around LDL-C.
It’s a standalone blood draw available at any major commercial lab. It costs $15 to $30, doesn’t require fasting, and produces a single number that has greater predictive value than the traditional lipid panel. The rate-limiting step is the physician’s awareness of the test.
If your doctor doesn’t order an ApoB test, ask for it. At an annual executive health screening or a routine visit, adding ApoB to the lab order takes seconds and can change the trajectory of your cardiovascular care.
Today’s Takeaways
The ApoB test is the cardiovascular equivalent of adopting the metric system: a more accurate, more practical measurement that the rest of the developed world has already embraced. The U.S. is catching up, but inertia is slow to overcome.
If you have a lipid panel that looks “normal” but carries metabolic risk factors, an ApoB result might tell a different story. If you’re already managing cardiovascular risk with lifestyle changes and medication, ApoB provides a sharper lens for evaluating your progress.
At Banner Peak Health, we include ApoB in our standard cardiovascular risk assessments. We continue to evaluate and implement advanced diagnostic tools to reduce coronary artery risk.
But don’t worry: we’ll still discuss your weight in pounds and not kilograms, if that’s what you prefer.
Contact Banner Peak Health to discuss ApoB testing and your cardiovascular risk profile.
How to Read Your Calcium Score Test: What 0 to 1,000 Means
I’ve been studying medicine for 40 years and have treated thousands of patients. I’ve learned you don’t fully grasp the meaning of a diagnosis until you or a family member has lived it.
All healthcare exists on two planes: biology (our bodies) and psychology (how we feel about our bodies). My experience transitioning from a negative to a positive calcium score test gave me new insight into both.
I’ve always been thin and athletic, carrying a self-image of being a “healthy guy.” At 54, I underwent a coronary artery calcium scan and received a score of zero: no detectable calcium in my coronary arteries.
No other risk factors flagged. My identity as “the healthy guy” was reinforced.
Seven years later, I repeated the scan. This time, my score came back at 14, mildly positive on a scale of zero to 1,000.
Even that small number changed my self-perception. A positive score meant I was developing atherosclerosis in my coronary arteries, a process likely occurring throughout arteries in my body.
I reviewed my cholesterol panel, which showed no red flags: total cholesterol 185, HDL 49, LDL 127, ApoB 102. None of those numbers screamed danger.
But given the positive calcium score, the cholesterol values became less important. My body was developing coronary artery disease regardless of how “okay” my panel looked.
In consultation with my doctor, I started a low-dose statin: half of a 5mg rosuvastatin (Crestor) tablet daily. My repeat cholesterol panel was striking: total cholesterol 145, HDL 50, LDL 82, ApoB 72, with a 30–35% reduction in LDL and ApoB. That medication reduced my risk of a major cardiac event by 20–30%.
My perception of being a “healthy guy” was dented. But I was 20–30% less likely to have a heart attack and die, and the peace of mind of knowing I’m slowing down the clogging of my pipes has independent value. Without that scan, I never would have known.
When Blood Work Isn’t Enough
A standard annual blood panel, including HDL, LDL, triglycerides, and (if your doctor orders it) ApoB, gives you a statistical estimate of future risk. If those numbers fall in the normal range, it’s natural to feel reassured.
The problem: Approximately half of all MI patients present with LDL cholesterol levels that are not considered elevated (LDL-C <100 mg/dL). Routine blood work alone doesn’t catch them.
A lipid panel estimates the statistical probability of what might happen; a calcium score test shows what is already happening. The distinction is the difference between a weather forecast and looking out the window. One predicts; the other confirms.
How the Calcium Score Test Works
Calcium is radio-opaque, meaning X-rays can’t pass through it. A CT scan (a three-dimensional X-ray) exploits this property to image calcium deposits in the coronary arteries.
The calcium score test is one of the simplest and most informative cardiac screenings available. No IV, no contrast dye, no treadmill. You lie on a table, hold your breath, and in fewer than 10 minutes, you’re done.
The result is a single number, your Agatston score, on a scale from zero to over 1,000.
This screening sits in a unique space. A standard executive physical might include detailed blood work and a physical exam, but few panels directly image the coronary arteries. The scan fills that gap.
What the Scores Mean
The Agatston score is divided into ranges, each with a different clinical implication:
- A calcium score test result of zero means no detectable plaque and a very low probability of a cardiac event in the next 10 years. This is the best possible outcome. It doesn’t guarantee immunity from heart disease, but it’s strongly reassuring.
- A score of one to 99 indicates a small amount of plaque. The pipes are starting to clog, and it’s a signal to take prevention seriously. Lifestyle modification is the first step. For some patients, this range tips the conversation toward medication, particularly statins. After nearly 40 years of clinical experience with this drug class, the risk-benefit profile of statins remains among the most favorable in medicine, with side effects that are rare and typically reversible (most commonly muscle aches, similar to those with other cardiac medications).
- A score of 100 to 399 signals moderate plaque buildup. The 10-year risk of a cardiovascular event is meaningfully elevated, and medication is typically warranted.
- A score of 400 to 999 carries an even higher plaque burden. Aggressive prevention is the appropriate course.
- A score of 1,000 or above demands immediate, aggressive intervention.
How to Read Your Percentile Rank
The report will include a second number: your percentile rank. This compares your score with those of other people of your age and gender.
For example, my score of 14 at age 61 put me in the 33rd percentile, meaning 33 out of 100 theoretical men my age would have had less coronary calcium, and 67 would have had more. If that same score of 14 had occurred at age 40, it would have placed me in the 90th to 95th percentile, worse than 90 to 95% of the age- and gender-matched cohort. Same absolute number, vastly different clinical significance.
The percentile tells you how far along the atherosclerosis progression you’ve traveled relative to your peers. But a common trap exists here: “normal” or 50th percentile might still indicate elevated risk.
In a society with high rates of hyperlipidemia, average doesn’t mean optimal. We’ve explored this theme in our discussion of healthy vs. normal cholesterol ranges, and the same logic applies.
Your calcium score percentile rank shows where you stand on the atherosclerosis continuum compared to others your age, but “average” in an unhealthy population isn’t a number you want to settle for.
Taking Action
The gift of this scan is knowledge. The next step is a careful conversation with your doctor about your cardiovascular risk profile, personal preferences, and a plan moving forward.
In my own case, the positive score prompted a statin that cut my LDL and ApoB by 30 to 35%. That kind of reduction, paired with lifestyle strategies like fish oil supplementation for cardiovascular risk and regular exercise, compounds over time. The benefit at 10 years is meaningful, and beyond 10 years, the risk reduction grows substantially as the baseline risk climbs with age.
Use the data from your calcium score test as the starting point for a risk-reduction conversation with your physician. Don’t let a positive score spiral into fear, and don’t let a zero score create false complacency.
Why Isn’t the Calcium Score Test Standard?
The calcium score test costs approximately $100 to $250 out of pocket, takes fewer than 10 minutes, and carries a radiation dose comparable to a mammogram. By most measures, it’s one of the most powerful cardiovascular screens available.
Insurance rarely covers it. Explaining why would require a separate article and leave nobody feeling cheerful. If you have the financial resources, this is one of the best places to put your healthcare dollar.
Today’s Takeaways
My story follows a familiar arc: a “healthy guy” with a normal-looking cholesterol panel who, without the calcium score test, would have missed the early signs of coronary artery disease. Half of all heart attacks happen to people in exactly that position.
The test is fast, inexpensive, and low-risk. The number it produces, your Agatston score, moves the conversation from statistical estimates to anatomical reality. It can guide cardiovascular risk management in a way no blood test alone can.
Ask your doctor about it. And if your doctor doesn’t bring it up, ask anyway. The rate-limiting step isn’t the test itself; it’s the awareness to order it.
At Banner Peak Health, we run calcium score testing as part of our standard cardiovascular risk assessment. Contact Banner Peak Health to discuss whether this screening makes sense for you.
Is a Whole Body MRI Worth It? A Physician’s Honest Take
Is sunshine good or bad?
The honest answer depends on context, degree, and perspective. Sunshine grows crops, powers solar energy, and lifts our mood. It can also cause skin cancer, contribute to drought, and accelerate climate change.
Most medical decisions operate in this same gray area, yet we crave binary verdicts: good or bad, safe or dangerous, worth it or not. Whole body MRI doesn’t fit neatly into either column.
Direct-to-consumer marketing has fueled a boom in these scans, with standalone centers offering these screenings for $1,000 to $2,000, no physician referral required. The pitch positions the scan as a sort of do-it-yourself executive physical: detect problems early and buy yourself peace of mind.
Peace of mind is a powerful promise. For most people, the math tells a different story, one in which a whole body MRI creates more anxiety than it resolves.
What a Whole Body MRI Can and Can’t Detect
The scan performs well at detecting solid organ tumors in the kidney, liver, and prostate. It can identify intracranial aneurysms (dangerous dilations in the brain with rupture potential) and soft tissue masses, all without ionizing radiation, a meaningful advantage over CT-based screening.
The modality does find cancer. A 2026 meta-analysis in European Radiology, reviewing data from 9,000 asymptomatic individuals, found a cancer detection rate of 1.57%.
For specific high-risk genetic conditions, the evidence supports routine screening. NCCN guidelines recommend annual screening MRI for individuals with Li-Fraumeni syndrome, a genetic predisposition carrying an elevated risk of solid tumors. In this select population, the scan earns its place in a proactive cancer prevention plan.
Whole body MRI can detect solid organ tumors and brain aneurysms without radiation, but it can’t replace targeted screenings for the most common cancers. Colon cancer, breast cancer, and thyroid cancer each require dedicated screening modalities: colonoscopy, mammography, and ultrasound. A clean scan result can create a false sense of security and leave these cancers undetected.
Screening vs. Diagnostic: Why the Distinction Matters
A diagnostic MRI starts with a hypothesis. Your physician suspects a lesion, a symptom points to a specific organ, and the scan focuses on answering a targeted clinical question.
A screening MRI is the opposite: a fishing expedition. No specific symptom or finding prompted the scan. The modality sweeps across the entire body looking for any abnormality.
Knowing the difference between a screening MRI and a diagnostic MRI changes how you interpret the results. The purpose and recommended frequency of medical testing change dramatically depending on whether you’re screening a healthy population or diagnosing a symptomatic patient. Screening a low-risk population with a broad-sweep imaging tool produces a flood of false positives.
The Math Behind a Whole Body MRI
Approximately one-third of asymptomatic adults who undergo this screening have incidental findings: liver cysts, renal cysts, disc bulges, uterine fibroids. These findings look alarming on a report, but they aren’t cancer. The false positive rate is the central problem with whole body MRI screening.
Consider a hypothetical scenario: 1,000 healthy 45-year-olds with no elevated cancer risk undergo screening. With a cancer prevalence of 0.2% (two people in 1,000 with actual cancer), a sensitivity of 90%, and a specificity of 68%, the numbers break down like this:
- Two people receive true positive results. They have cancer, and the scan found it.
- 319 people receive false positive results. The scan flagged an abnormality that isn’t cancer.
The positive predictive value (the probability that a positive result is truly positive) is 0.6%. If you put those 321 people with positive results in a room and tell them they might have cancer, only two of them actually do.
This math isn’t unique to this modality. It’s a principle of probability that applies to every screening and diagnostic test.
Any test’s usefulness depends on how likely you were to have the disease before the test. When you screen a low-risk population, even a sensitive test generates more false alarms than real diagnoses.
The False Positive Cascade
Those 319 false positives don’t end with an email and a shrug. Each one triggers a cascade of follow-up steps, each carrying its own costs in time, money, and emotional toll.
First comes the notification: a phone call informing you of a finding that “might be cancer, might not be.” Anxiety begins immediately. Next, follow-up imaging: a contrast-enhanced MRI or CT scan that costs thousands of dollars and takes weeks to schedule, all with uncertainty hanging overhead.
Depending on the finding’s location and appearance, a specialist consult may follow. Then, potentially, a biopsy, an invasive procedure with its own physical risks. If the biopsy proves inconclusive, the next step is serial surveillance: reimaging at three, six, or 12 months.
For the overwhelming majority of those 319 people flagged by the screening scan, weeks or months of heightened stress and physiological strain, thousands in additional testing, and the physical risk of invasive procedures end with the same answer: no cancer. The promise of peace of mind delivered its opposite.
The Direct-to-Consumer Problem
A standalone scanning company collects $1,000 to $2,000, performs the scan, hands over a report, and walks away from the relationship. Your existing healthcare team is then responsible for the entire workup cascade described above. This is the “take the money and run” model of healthcare.
Direct-to-consumer whole body MRI centers profit from scanning as many people as possible, regardless of individual appropriateness. A for-profit center won’t decline a paying customer whose risk profile doesn’t justify the test.
Watch for these red flags before booking a scan. No pre-scan clinical assessment means nobody evaluated whether you’re a good candidate. No follow-up infrastructure means “contact your healthcare provider” printed on a results page passes the burden to you and your doctor.
Promises of “peace of mind” contradict what the numbers show for low-risk individuals. Marketing built on celebrity endorsements or single success stories doesn’t negate probabilistic math.
A concierge medical practice takes a different approach: a physician who knows your history orders the test, frames your pre-test probability, and owns whatever the scan finds.
Today’s Takeaways on Whole Body MRI Scans
The whole body MRI question depends on your clinical context and your pre-test probability of cancer. It depends on your personality and tolerance for the anxiety that comes with a modality heavy with false positives. It depends on whether your healthcare environment can adequately work up an incidental finding.
For individuals with genetic syndromes carrying elevated cancer risk, the math is different. When the pre-test probability rises from 0.2% to 10%, the positive predictive value can climb to 50%: one false positive for every true positive. For these patients, the scan earns its place.
The same logic applies to aneurysm screening. The false positive rate remains high, and no evidence demonstrates improved mortality in average-risk populations.
For the average healthy adult without elevated risk, the odds stack against benefit. A whole body MRI is extra sauce in a layered early detection strategy, not the main course. Don’t let a slick advertisement replace a conversation with your doctor.
Have questions about advanced diagnostic screening? Contact Banner Peak Health to discuss whether this or any screening makes sense for your individual risk profile.
Peptide Therapy: A Doctor’s Warning About the Gray-Market Trend
Peptide therapy is the talk of the town right now. It shows up in wellness influencer feeds, online sellers, and clinic offerings. Most of what’s being sold isn’t proven, isn’t regulated, and doesn’t belong in anyone’s body.
The story everyone wants to tell is about the therapeutic potential of these compounds. The harder story, and the one worth telling, is about how patients, physicians, and society decide what goes into our bodies.
Here’s the short answer on gray-market peptides like BPC-157, TB-500, and CJC-1295: I don’t recommend them. The longer answer says more about how we think about evidence and hype than about any one compound. Patients curious about where the line falls between approved GLP-1 medications and gray-market versions will find that distinction is at the heart of the matter.
What Are Peptides?
A peptide is a chain of amino acids, the same building blocks that make up proteins in the body. Think of beads on a string, 20 to 50 long, folding into a three-dimensional shape that gives the molecule its function.
These small structures act as chemical messengers, regulating hunger, blood sugar, growth, and immune function. The body produces thousands of them. Insulin is the most familiar peptide hormone in the body, the one that controls blood sugar.
Beyond what the body produces, more than 80 peptide drugs hold FDA approval, with hundreds more in development. These are well-studied medications used in mainstream medicine, with documented safety and efficacy.
FDA-Approved Peptides vs. Gray-Market Peptides
Approved peptide drugs come with substantial clinical data. The GLP-1 agonists semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have both been studied in tens of thousands of patients across the STEP and SURMOUNT Phase 3 programs, alongside tesamorelin (Egrifta) and other approved peptide drugs. Their production is regulated for safety and purity.
Gray-market peptides sit on the other side of the line. Compounds like BPC-157 (body protection compound), TB-500 (a fragment of thymosin beta-4), and CJC-1295 (marketed for growth hormone release) are sold online without FDA approval. These peptides carry a “for research use only” label, which sidesteps FDA oversight as they reach consumers.
The label is the epitome of irony. A compound marked for “research” and then injected into people without any valid human studies has the worst of both worlds: no oversight and no proof.
For a clear contrast to the gray-market approach, read our guide on how to make safe choices with supplements.
The Risks of Gray-Market Peptides
The risks break into two categories. The first is the biological risk of the compounds themselves. The second is contamination and poor manufacturing.
On the compound side, growth hormone-releasing peptides like CJC-1295 carry a theoretical risk of insulin resistance, joint pain, fluid retention, and abnormal tissue growth, the medical euphemism for cancer. TB-500 and related peptides that promote blood vessel growth carry a parallel theoretical risk of stimulating tumor growth, with no human studies to quantify its magnitude.
The manufacturing risk is documented rather than theoretical. Testing of gray-market peptide products has reported purity levels ranging from 5% to 75%. The unknown remainder includes arsenic, lead, and other heavy metals, as identified in independent testing.
Bacterial contamination raises the stakes further. Injection beneath the skin bypasses the body’s first lines of immune defense, so the risk of infection runs well above that of oral medications. The combination of unknown purity and infection risk makes any individual gray-market peptide injection unpredictably dangerous.
The Decision Behind Peptide Therapy
Decisions about what to put in our bodies happen at three levels: the individual, the physician, and society.
Individual decisions sit at the center. Personal beliefs shape them, including religious and philosophical views on foreign substances, comfort with new technology, and personal risk tolerance. External forces shape them, too, including family, friends, social media, influencers, podcasts, and institutional medicine.
Physicians sit further from the action than we tend to think. The medical community overestimates its own influence on individual decisions and underestimates the role of social and cultural forces. The peptide trend exists at this intersection, where individual choice, social signals, and the limits of physician influence collide.
What COVID Taught Us About the Peptide Trend
The COVID vaccine experience taught the medical community a hard lesson about evidence and influence. Billions of doses had been administered worldwide following thousands of studies, with overwhelming evidence that the benefits exceeded the risks, yet vaccine hesitancy remained substantial enough to fuel a political movement.
The medical community learned that most people don’t think the way physicians do, and that scientific evidence has limits as a driver of individual choice. Group thinking, personal experience, and social signals carry as much weight as data, and often more.
Peptides show the same pattern in reverse: evidence is thin, yet the wave of interest and use keeps building. A dangerous combination drives the trend: plausible biology, compelling anecdotes, and insufficient data.
Today’s Takeaways
Gray-market peptides are not on my recommendation list. The evidence base is thin, the manufacturing is unreliable, and the risks are documented enough to take seriously.
The deeper lesson from the peptide trend is about how to think through medical decisions when the marketplace is loud and the data is quiet. Slow down and ask what’s been studied, by whom, at what scale, with what oversight.
For gray-market peptides, that answer is not enough.
At Banner Peak Health in Walnut Creek, we work with patients on exactly this kind of question. To talk through a specific peptide or treatment that’s caught your interest, reach out to our practice.
Frequently Asked Questions About Peptides
Are peptides safe?
FDA-approved peptide drugs like semaglutide and tirzepatide have substantial safety data from tens of thousands of patients. Gray-market peptides like BPC-157, TB-500, and CJC-1295 lack human trials and carry documented risks from both the compounds themselves and from manufacturing contamination.
Is BPC-157 legal in the United States?
BPC-157 is not FDA-approved for human use. The compound is sold online with a “for research use only” label, which sidesteps FDA oversight and allows it to reach consumers without the safety and efficacy review that approved drugs go through.
What’s the difference between FDA-approved peptides and gray-market peptides?
FDA-approved peptides have been studied in tens of thousands of patients with documented safety and efficacy, and their production is regulated for purity. Gray-market peptides are sold online without regulatory oversight, and independent purity testing of gray-market products has reported values as low as 5% and ranging up to 75%, with the remainder consisting of arsenic, lead, and other heavy metals.
Why are gray-market peptides risky to inject?
Injection bypasses the body’s first lines of immune defense, raising the risk of infection well above that of oral medications. Combined with unknown compound purity and documented heavy-metal contamination, any individual gray-market peptide injection becomes unpredictably dangerous.